During pregnancy, the maternal immune system must engage in a fine balancing act: maintaining tolerance to the fetal ...
Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI ® and SYFOVRE ®, while Apellis’ talent and expertise will accelerate Biogen’s entry ...
Zurich, Zurich - April 10, 2026 - PRESSADVANTAGE - IntroDrink, the Swiss premium natural health retailer, has expanded ...
Washington: The researchers at the University of Chicago have uncovered a surprising new role for zeaxanthin, a plant-based ...
Both protein and fiber are in the spotlight right now for good reason. But which should you prioritize? Dietitians explain ...
Awarded to Dr Hayley Lavender (pictured right) and Dr Paraskevi (Pari) Kritsiligkou, the awards support biomedical ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Biogen said Tuesday that it would buy Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, expanding its portfolio with a set of approved immunology drugs. Cambridge-based Biogen ...
EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...
Two researchers from the University of Liverpool's Faculty of Health and Life Sciences have been awarded prestigious ...
A common eye-health nutrient, zeaxanthin, may also help the body fight cancer more effectively. Scientists discovered it strengthens T cells and enhances the impact of immunotherapy treatments. Found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results